Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of ...